QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
Retrieved on:
Wednesday, April 10, 2024
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Medical Devices, Hospitals, Urine, Addiction, Mortality, University, Fentanyl, Risk, Hospital, CDC, 7600, UMD, XT, Substance Abuse, Fatality, Medicine, Multimedia, Maryland School, Assistant, QuidelOrtho, Pharmaceutical industry
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay (“MPA”).
Key Points:
- QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay (“MPA”).
- This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.
- As part of QuidelOrtho’s Vitros systems’ menu of assays, the test offers clinical fentanyl testing for hospitals and emergency departments, providing an effective approach to preliminary urine drug testing.
- When patients test positive for opioids on a standard drug test, they’re usually directed to drug treatment programs.